Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study.

CKD progression GFR decline Urine osmolality biomarker chronic kidney disease (CKD) end-stage renal disease (ESRD) glomerular filtration rate (GFR) measured GFR (mGFR) prognostic factor tubular damage urine concentration ability

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
05 2019
Historique:
received: 05 06 2018
accepted: 01 12 2018
pubmed: 20 2 2019
medline: 1 2 2020
entrez: 20 2 2019
Statut: ppublish

Résumé

Chronic kidney disease (CKD) characterized by decreased glomerular filtration rate (GFR) is often accompanied by various degrees of impaired tubular function in the cortex and medulla. Assessment of tubular function may therefore be useful in establishing the severity of kidney disease and identifying those at greater risk for CKD progression. We explored reductions in urinary concentrating ability, a well-known feature of CKD, as a risk factor for GFR decline and end-stage renal disease (ESRD). Prospective longitudinal cohort study. 2,084 adult patients with CKD stages 1 to 4 from the French NephroTest Cohort Study. Fasting urinary osmolality measured using delta cryoscopy. ESRD, mortality before ESRD, and measured GFR (mGFR) assessed using Cause-specific hazards models were fit to estimate crude and adjusted associations of urinary osmolality with ESRD and death before ESRD. Linear mixed models with random intercepts were fit to evaluate the association of urinary osmolality with slope of decline in mGFR. At baseline, mean age was 58.7±15.2 (SD) years with a median mGFR of 40.2 (IQR, 29.1-54.5) mL/min/1.73m Fasting was self-reported. Fasting urinary osmolality may be a useful tool, in addition to GFR and albuminuria, for assessing nonglomerular damage in patients with CKD who are at higher risk for CKD progression.

Identifiants

pubmed: 30777634
pii: S0272-6386(19)30004-6
doi: 10.1053/j.ajkd.2018.12.024
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

596-604

Investigateurs

Marine Livrozet (M)
Emmanuel Letavernier (E)
Pierre Ronco (P)
Hafedh Fessi (H)
Emmanuelle Vidal-Petiot (E)
Eric Daugas (E)
Caroline du Halgouet (C)
Renaud de La Faille (R)
Gerard Maruani (G)
Marion Vallet (M)
Laurence Nicolet-Barousse (L)
Alexandre Karras (A)
Christian Jacquot (C)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Nahid Tabibzadeh (N)

Sorbonne Université, Inserm UMR_S 1155, Paris, France; Unit of Renal Physiology, AP-HP Hôpital Tenon, Paris, France.

Sandra Wagner (S)

CESP, Inserm U1018, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Villejuif, France; FCRIN INI-CRCT, France.

Marie Metzger (M)

CESP, Inserm U1018, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Villejuif, France.

Martin Flamant (M)

Université Paris Diderot, Paris, France; Unit of Renal Physiology, AP-HP Hôpital Bichat, Paris, France.

Pascal Houillier (P)

Université Paris Descartes, INSERM UMR_S1138, Paris, France; Unit of Renal Physiology, AP-HP Hôpital Européen Georges Pompidou, Paris, France.

Jean-Jacques Boffa (JJ)

Sorbonne Université, Inserm UMR_S 1155, Paris, France; Unit of Nephrology, AP-HP Hôpital Tenon, Paris, France.

Francois Vrtovsnik (F)

Université Paris Diderot, Paris, France; Unit of Nephrology, AP-HP Hôpital Bichat, Paris, France.

Eric Thervet (E)

Université Paris Descartes, INSERM UMR_S1138, Paris, France; Unit of Nephrology, AP-HP Hôpital Européen Georges Pompidou, Paris, France.

Bénédicte Stengel (B)

CESP, Inserm U1018, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Villejuif, France; FCRIN INI-CRCT, France. Electronic address: benedicte.stengel@inserm.fr.

Jean-Philippe Haymann (JP)

Sorbonne Université, Inserm UMR_S 1155, Paris, France; Unit of Renal Physiology, AP-HP Hôpital Tenon, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH